Premium Adjustments: Rising treatment costs could lead insurers to increase premiums or out-of-pocket expenses for policyholders
While 503B facilities are required to follow current Good Manufacturing Practices (cGMP), the compounded drugs themselves are not FDA-approved. If semaglutide and tirzepatide are removed from the 503B bulks list, the availability of compounded GLP-1s would drop significantly, Michael Snyder, MD, FACS, FASMBS, DABOM, medical director of the Bariatric Surgery Center at Rose Medical Center, founder and director of the Denver Center for Bariatric Surgery Foundation, and in-house obesity specialist at FuturHealth, told MNT
International Journal of Molecular Sciences, 20(21), 5407
Yet weight has been shown to be a major factor in long-term health